-
European Hematology Association (EHA) 2024 Wrap-Up: A Confluence of Innovation and Collaboration
The European Hematology Association (EHA) 2024 has concluded, leaving a trail of impactful insights and advancements in the field of hematology.Highlights included innovative therapies for blood cancers, breakthroughs in stem…
-
Machine Learning Enhances Cancer-Specific CVD Risk Prediction
A recent study published in JNCI Cancer Spectrum (Jan 2025) introduces a machine learning-based cancer-specific cardiovascular disease (CVD) risk score, designed to improve risk prediction for breast, colorectal, and lung…
-
BOC/BOA 2024 | Professor Zhixiang Shen: Strengthening Innovation and Integrating Breakthroughs into Clinical Practice
From July 5th to 7th, the 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China (BOC/BOA 2024) were grandly held in Guangzhou. The conference gathered domestic oncology experts and related professionals to witness the past year’s research progress in clinical oncology in China and discuss the future innovative…
-
Real-World Comparison of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
A newly published study in ESMO Open (Jan 2025) led by H. S. Rugo, R. M. Layman, F. Lynce, G. Curigliano, A. Brufsky, and colleagues analyzed real-world overall survival (OS)…
-
BOC/BOA 2024 | Professor Donglu Zhao: Annual Progress in the Field of Hematologic Oncology in China
From July 5th to 7th, the “2024 Annual Progress Seminar in Clinical Oncology in China (BOC),” hosted by the Chinese Society of Clinical Oncology (CSCO), was held in Guangzhou. The conference invited numerous domestic oncology experts to highlight the “2023 Annual Progress in Clinical Oncology in China” selected by CSCO. Additionally, it focused on the…
-
Focus on Annual Advances in Clinical Oncology Research in the Field of Breast Cancer in China, Multidisciplinary Collaboration Boosts New Drug
From July 5-7, 2024, the 2024 China Annual Clinical Oncology Advances Symposium (BOC) and Beast of ASCO® 2024 China (BOC/BOA) were grandly held in Guangzhou. In the field of breast cancer, this conference brought together important research from the Chinese breast cancer field in 2023 and highlighted key advancements from the American Society of Clinical…
-
Hans Wildiers Leads AIPAC Trial on Eftilagimod Alpha in HR+/HER2- Metastatic Breast Cancer
Dr. Hans Wildiers and colleagues published findings from the AIPAC Phase IIb trial (Clin Cancer Res, Feb 2024), evaluating eftilagimod alpha (efti), a soluble LAG-3 protein, in combination with paclitaxel…
-
Professors Bing Chen and Lijuan Chen’s Team: FUMANBA-2 Study Opens New Horizons for Treating High-Risk Newly Diagnosed Multiple Myeloma
The 29th Annual Congress of the European Hematology Association (EHA) took place from June 13 to June 16, 2024, in Madrid, Spain. On the afternoon of June 15, local time, Professor Bing Chen from Nanjing Drum Tower Hospital affiliated with Nanjing University Medical School presented the latest data from the FUMANBA-2 study in an oral…
Connecting Medical Expertise through Media